52
Management
Figure 12. Consideration of Oral Anticoagulation for
Device-Detected AHREs According to Patient Stroke
Risk by CHA
2
DS
2
-VASc Score and Episode Duration
Short,
Rare AHREs
AHRE 6 min–5.5 hrs Observe for
AF development
Period assessment of
patient risk
• Other OAC
indication?
• Changes in CHADS-
VASc over time?
• Consider data from
commander HF,
COMPASS to refine
patient risk?
AHRE >5.5 hrs
AHRE >24 hrs
Low risk
CHA
2
DS
2
-VASc = 0 (men)
CHA
2
DS
2
-VASc = 0 (women)
A
SCAF/AHRE
Burden
ARTESiA, Apixaban for the Reduction of rombo-Embolism in Patients With Device-
Detected Subclinical Atrial Fibrillation trial; COMMANDER HF, A Study to Assess the
Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction,
or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an
Episode of Decompensated Heart Failure; COMPASS, Cardiovascular Outcomes for People
Using Anticoagulation Strategies; NOAH, Non-Vitamin K Antagonist Oral Anticoagulants in
Patients With Atrial High Rate Episodes Trial; and OAC, oral anticoagulation.
